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Abstract
Background: Phenylephrine (PHE), an α1 adrenergic receptor agonist, increases phospholipase D
(PLD) activity, independent of classical and novel protein kinase C (PKC) isoforms, in rat-1
fibroblasts expressing α1A adrenergic receptors. The aim of this study was to determine the
contribution of atypical PKCζ to PLD activation in response to PHE in these cells.
Results: PHE stimulated a PLD activity as demonstrated by phosphatidylethanol production. PHE
increased PKCζ translocation to the particulate cell fraction in parallel with a time-dependent
decrease in its activity. PKCζ activity was reduced at 2 and 5 min and returned to a sub-basal level
within 10–15 min. Ectopic expression of kinase-dead PKCζ, but not constitutively active PKCζ,
potentiated PLD activation elicited by PHE. A cell-permeable pseudosubstrate inhibitor of PKCζ
reduced basal PKCζ activity and abolished PHE-induced PLD activation.
Conclusion: α1A adrenergic receptor stimulation promotes the activation of a PLD activity by a
mechanism dependent on PKCζ; Our data also suggest that catalytic activation of PKCζ is not
required for PLD stimulation.
Background
Phospholipase D (PLD) is widely distributed in mamma-
lian cells and has been shown to be involved in signal
transduction, protein trafficking, cell proliferation, differ-
entiation and apoptosis [1-3]. PLD catalyzes the hydroly-
sis of phosphatidylcholine to phosphatidic acid and
choline. Activation of PLD by various agents has been
shown to involve small G-proteins of the Arf and Rho
families, protein kinase C (PKC) and phosphatidylinosi-
tol 4,5-biphosphate (PtdIns(4,5)P2) [1-3]. Two PLD iso-
forms have been cloned in humans and rats. PLD1
exhibits a low basal activity and is activated by Arf, RhoA
and PKC [4,5]. PLD2 has a high basal activity, requires
PtdIns(4,5)P2, and is not or is less responsive to Arf, Rho
or PKC than PLD1 [6,7].
Stimulation of α1 adrenergic receptors (AR) increases PLD
activity in rat tail artery [8] and MDCK cells [9]. In rat-1
fibroblasts expressing different subtypes of α1 AR, α1A AR
is more effectively coupled to PLD activation than other
α1 AR subtypes [10,11].
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The involvement of PKC in PLD regulation has been doc-
umented both in vivo and in vitro [1-3]. PKC isoforms are
classified on the basis of their protein sequences and bio-
chemical properties [12]. The classical PKC isoforms (α,
β1,β2 and γ) are activated by phosphatidylserine and dia-
cylglycerol (DAG) or phorbol esters in a calcium-depend-
ent manner. The novel PKC isoforms (δ, ε, Η and θ) are
activated by DAG or phorbol esters in the presence of
phosphatidylserine and in the absence of calcium. Classi-
cal and novel PKCs play a critical role in cell proliferation,
differentiation, tumorigenesis, and apoptosis and have a
multitude of cellular substrates with broadly overlapping
specificity [12,13]. The atypical PKC isoforms (ι/λ and ζ)
are both calcium- and DAG-independent [13]. PKCζ is a
critical mediator of mitogenic signaling in many cell types
[13-16]. The activation of PI3-kinase by growth factors
induces a moderate activation of PKCζ that is mediated by
phosphorylation at its T-loop site by PDK1 followed by a
subsequent autophosphorylation [17,18]. The activity of
PKCζ is reversibly regulated by an autoinhibitory pseudo-
substrate region in the regulatory domain, which blocks
the active site of the enzyme in the absence of activators,
a feature common to all PKCs [19]. In addition, the PKCζ
pseudosubstrate is able to interact with tubulin and p62/
ZIP protein [20,21]. PKCζ is activated by nonselective
binding of acidic lipids such as polyphosphoinositides
and phosphatidic acid, unsaturated fatty acids such as ara-
chidonic acid [12], and acidic proteins such as 14-3-3 pro-
teins [22]. In rat-1 fibroblasts, PKCζ mediates the
activation of ERK and the increase in mitogenesis elicited
by PDGF [15]. However, in rat-1 fibroblasts expressing the
α1A AR subtype, norepinephrine does not activate ERK
[23].
Classical PKC subtypes have been implicated in PLD acti-
vation in vitro or in cells overexpressing classical PKCs
[3,24]. However, there are reports indicating receptor-
mediated PLD activation that is independent of classical
PKCs [9,25]. PLD activation by classical PKCs in vitro does
not involve a phosphorylation mechanism [26]. It is cur-
rently unclear if the non-catalytic mechanism by which
PKCα and β activate PLD1 in vitro accounts for PKC-
dependent increases in PLD activity in intact cells [1-3].
We have previously reported that α1A adrenergic stimula-
tion of PLD in rat-1 fibroblasts is independent of classical
or novel PKCs [25]. Three recent articles have placed acti-
vation of atypical PKCs downstream of PLD, presumably
through phosphatidic acid generation [27-29]. On the
other hand, PKCζ mediates norepinephrine-induced PLD
activation in rabbit vascular smooth muscle cells (VSMC)
[30]. The present study was conducted to investigate the
relationship between PKCζ and PLD activation in
response to PHE in rat-1 fibroblasts expressing the α1A AR
subtype. Our study demonstrates that PHE stimulates a
PLD activity in rat-1 fibroblasts by a mechanism depend-
ent on the inactivation of PKCζ activity and suggests a role
for the pseudosubstrate domain.
Results
PHE and PMA stimulate PLD activity in rat-1 fibroblasts
Rat-1 fibroblasts stably transfected with α1A AR expressed
288 ± 2 fmol/mg protein of receptors [10]. PLD activity
was measured by the production of [3H]phosphatidyleth-
anol (PEt) in cells pre-labeled with [3H]oleic acid and in
the presence of ethanol. Basal PLD activity was deter-
mined in serum-starved cells in the presence of ethanol
and in the absence of any agonists. PLD activation in
response to PHE is characterized by a rapid initial rise (30
sec) followed by a slower rate of PEt formation [11]. PLD
activity was measured at 15 min and represents the accu-
mulation of PEt formed in vehicle or PHE-treated cells.
PHE elicited a concentration-dependent increase in PLD
activity (Fig. 1A). On the other hand, the phorbol ester
PMA produced a maximal increase at 100 nM (Fig. 1B), to
a significantly lesser extent than PHE. In rat-1 fibroblasts
expressing  α1A  AR, [3H]PEt/ [3H]total lipids ratio was
almost identical in the presence or absence of ethanol
(5.43 ± 0.52 vs. 4.53 ± 0.63 × 103 × [3H]PEt/ [3H]total lip-
ids, n = 8). Therefore, [3H]PEt/ [3H]total lipids ratio meas-
ured in the absence of ethanol may be accounted by non-
PLD pathways, as recently described [31]. PLD activity
was stimulated 4–5 times above basal by 2 µM PHE and
2.5 times by 1 µM PMA (Fig. 1C), concentrations chosen
for our experiments. Furthermore, when basal PEt forma-
tion was calculated by subtracting the residual radioactive
background found in the absence of ethanol by non-PLD
pathways (5.43-4.53 = 0.90 × 103 × [3H]PEt/ [3H]total lip-
ids), the magnitude of PLD activation with PHE was
increased from 4–5 to 30 times. It may be significant that,
in VSMC, basal PEt formation in untreated cells accounts
for half of the measured PLD activity [30], typical of a con-
stitutive PLD2-like activity in these cells [32], whereas, in
rat-1 fibroblasts, the presence of an inducible isoform is
most probable. The PLD isoform sensitive to α1A AR stim-
ulation in rat-1 fibroblasts is inhibited by cAMP through
a negative feedback mechanism [10]. On the other hand,
in VSMC, norepinephrine-induced PLD activity (64.95 ±
0.49 % over basal), which is mainly dependent on the
activation of PLD2 [32], is instead potentiated by the ade-
nylyl cyclase activator forksolin (91.64 ± 11.70 % above
basal). These results support our contention that the PLD
isoform activated by PHE in rat-1 fibroblasts may be dis-
tinct from PLD2.
PKCζ is inactivated in response to α1A-adrenergic 
stimulation
To gain more insight into the effect of PHE on these PKC
isoforms, we measured the distribution of PKCα and
PKCζ between the cytosolic and particulate cellular frac-
tions by Western blot analysis. PKCα localization,BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/4
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Phospholipase D (PLD) activity is stimulated by phenylephrine (PHE) and PMA in rat-1 fibroblasts Figure 1
Phospholipase D (PLD) activity is stimulated by phenylephrine (PHE) and PMA in rat-1 fibroblasts. Cells in 
serum-free DMEM were incubated overnight with 1 µCi/ml [3H]oleic acid, pretreated with 200 mM ethanol (A, B) or with or 
without ethanol (C) for the measurement of phosphatidylethanol (PEt) formation, and finally treated with different concentra-
tion of PHE (A, basal = 7.09 ± 2.68 × 103 × [3H]PEt / [3H]total lipids) or PMA (B, basal = 6.81 ± 2.07 × 103 × [3H]PEt / [3H]total 
lipids) for 15 min. Data are expressed as the ratio of [3H]PEt over [3H]total lipids. Values are the mean ± S.E. of three inde-
pendent experiments performed in duplicate. * Value significantly different from vehicle, p < .05.
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Effect of PHE and PMA on PKCα localization in rat-1 fibroblasts Figure 2
Effect of PHE and PMA on PKCα localization in rat-1 fibroblasts. Serum-deprived cells in DMEM were treated with 2 
µM PHE or 1 µM PMA for 2, 5, 10 and 15 min, lysed and cytosol and particulate fractions were subsequently prepared as 
described in methods. A representative Western blot is shown in A. The bar graph (B) represents quantitation of the PKCα 
protein bands by densitometric analysis of blots from five different experiments. * Value significantly different from time = 0 
(cytosol or particulate), p < .05.
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Effect of PHE and PMA on PKCζ localization in rat-1 fibroblasts Figure 3
Effect of PHE and PMA on PKCζ localization in rat-1 fibroblasts. Serum-deprived cells in DMEM were treated with 2 
µM PHE or 1 µM PMA for 2, 5, 10 and 15 min, lysed and cytosol and particulate fractions were subsequently prepared as 
described in methods. A representative Western blot is shown in A. The bar graph (B) represents quantitation of the PKCζ 
protein bands by densitometric analysis of blots from five different experiments. * Value significantly different from time = 0 
(cytosol or particulate), p < .05.
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measured at different times after PHE stimulation, was
not significantly altered despite a slight decrease in
cytosolic fraction and a corresponding increase in particu-
late fraction (Fig. 2). PMA, included as positive control,
promoted PKCα translocation from the cytosol (-80%) to
the particulate (+200%) (cytoskeleton/membrane) frac-
tion (Fig. 2). We have previously reported the lack of
change in classical PKC activity in response to 2 µM PHE
in membrane/cytosolic fractions in these cells [25]. The
location of PKCζ was examined under the same condi-
tions. A small amount of PKCζ was translocated to the
particulate fraction following treatment with PHE, reach-
ing statistical significance only at 15 min of treatment
(Fig. 3). PMA did not significantly increase PKCζ translo-
cation. Therefore, based on the present study and previous
work by others [11] and ourselves [25], we conclude that
the translocation of PKCs as an index of their activation by
PHE is sufficient for PKCα, but PKCζ requires different
methods.
The phosphorylation of PKCζ on Thr 410, a PDK1-
dependent phosphorylation site, is required for PKCζ acti-
vation [17]. However, PKCζ phosphorylation at Thr 410
was already detected in serum-deprived rat-1 fibroblasts
and remained essentially unchanged in the presence of
PHE (Fig. 4). In contrast, we have previously shown that
norepinephrine promoted an increase of Thr 410 phos-
phorylation in a time-dependent manner in parallel with
an increase in PKCζ activity in VSMC [30]. The other atyp-
ical isoform, PKCλ/ι, is not expressed in rat-1 fibroblasts
[15]. Since only a small fraction of PKCζ was translocated
to the particulate fraction and the Thr 410 phosphoryla-
tion was not altered, we measured the change in kinase
activity of PKCζ in response to PHE. PKCζ activity was
measured by the ability of immunoprecipitated PKCζ to
phosphorylate a selective substrate in the presence of
[γ32P]ATP. We have previously shown PKCζ activation in
response to norepinephrine in rat VSMC using the same
method [30]. In contrast to the increase in PLD activity,
PHE decreased PKCζ activity at 2 and 5 min; activity
returned to sub-basal level within 10–15 min (Fig. 5A). In
conclusion, the decrease in PKCζ activity did not correlate
with a decrease in the phosphorylation of PKCζ at Thr
410. These results suggest that although phosphorylation
at Thr 410 and subsequent autophosphorylation of Thr
560 is a prerequisite for PKCζ activation, as shown in
other cell systems [17,18], dephosphorylation of Thr 410
is not a prerequisite for its inactivation.
To gain more insight into the mechanism of PKCζ regula-
tion by PHE, we measured PKCζ activity in immunopre-
cipitates from cells pretreated with myristoylated PKCζ
peptide inhibitor (PSζ) [33]. Myristoylated PSζ reduced
basal PKCζ activity and prevented its further decrease by
PHE (Fig. 5B), confirming that PKCζ is active in untreated
cells arrested in serum-free medium. It should be noted
that PHE produced a significantly greater decrease in
PKCζ activity than myristoylated PSζ, alone or with PHE,
pointing to a closely regulated mechanism of PHE-
induced PKCζ inactivation. Together, these results show
that PHE inhibits PKCζ and simultaneously activates PLD
in rat-1 fibroblasts.
Effect of PKCζ on PLD activity
Since 1) PKCζ activity was decreased by PHE, 2) PLD
activity was increased by PHE and 3) previous results
showed the lack of classical and new PKC contribution to
PHE-induced PLD activation [25], we tested the hypothe-
sis that PKCζ regulates PLD activity in rat-1 fibroblasts.
The contribution of PKCζ to PHE-induced PLD activation
was determined with transient expression of wild type
(wt), kinase deficient (T410A) and constitutively active
(T410E) PKCζ. The efficiency of FLAG-PKCζ transfection
after 48 hours was assessed by Western blot analysis (Fig.
6A). Overexpression of constitutively active T410E PKCζ
caused a statistically significant decrease in basal PLD
activity (Fig. 6B) whereas wt and T410A PKCζ did not
alter PLD activity. However, the apparent inhibition of
basal PLD activity observed with T410E PKCζ may be an
artifact since Fig. 1C clearly shows that PLD activity (PEt
formation) is not significantly reduced in the absence of
ethanol in vehicle. Therefore, it appears that T410E PKCζ
decreases the non-PLD product co-migrating with phos-
phatidylethanol in rat-1 fibroblasts. This observation
raises the possibility that T410E PKCζ does not decrease
PLD activity but only the non-PLD part. We therefore cal-
culated a PHE-induced PLD activity corrected for each
basal PLD activity observed in presence of the different
PKCζ constructs (Fig. 6C). Figure 6, panel C clearly shows
the absence of effect of T410E PKCζ on the extent of PHE-
induced PLD activity. On the other hand, we observe a sig-
nificant potentiation of PHE-induced PLD activity with
kinase-deficient T410A PKCζ. Thus, inactivation of the
catalytic activity of PKCζ potentiated PHE-induced PLD
activity suggesting a negative correlation between PKCζ
and PLD activities. This is compatible with the decrease in
PKCζ activity (Fig. 5A) elicited by PHE together with the
simultaneous increase in PLD activity. These results raise
the possibility that PKCζ catalytic activity is a negative reg-
ulator of α1A  AR-stimulated PLD activity in rat-1
fibroblasts.
PHE stimulates p38 MAP kinase activation in rat-1 fibrob-
lasts expressing α1A AR [23]. We have also measured p38
phosphorylation in response to PHE in cells transfected
with wild-type, kinase inactive (T410A) or constitutively
active (T410E) PKCζ to rule out an effect of heterologous
PKCζ overexpression on α1A AR signaling or function (Fig.
7). The results show that heterologous expression of PKCζ
did not alter p38 phosphorylation in response to 2 µMBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/4
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Effect of PHE on PKCζ phosphorylation at Thr 410 Figure 4
Effect of PHE on PKCζ phosphorylation at Thr 410. Cells were arrested for 48 hours and incubated for different time 
with 2 µM PHE. Samples were prepared for Western blot analysis and incubated with a phospho-PKCζ/ (Thr 410/403) anti-
body (A, top) as described in Methods. The same membranes were stripped off and reprobed with PKCζ antibody (A, bot-
tom). The bar graph (B) represents quantitation of the ratio phospho-PKCζ/ PKCζ protein bands by densitometric analysis of 
blots from three different experiments. No statistically significant differences were found.
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PHE decreases PKCζ activity in rat-1 fibroblasts Figure 5
PHE decreases PKCζ activity in rat-1 fibroblasts. A, Cells were treated with 2 µM PHE for 0, 2, 5, 10 and 15 min, lysed 
and immunoprecipitated with PKCζ antibody for a kinase assay using [γ-32P]ATP and a selective peptide substrate as described 
in Methods. Relative PKCζ activity was expressed as the fold (increase or decrease) of basal. Values are the mean ± S.E. of four 
independent experiments. * Value significantly different from the basal, p < .05. B, Effect of myristoylated PSζ on PKCζ activity. 
Cells were pretreated with 50 µM PSζ for 1 hour followed by a 5 min treatment with 2 µM PHE or its vehicle. PKCζ activity 
was measured as previously described. Values are the mean ± S.E. of four independent experiments. * Value significantly differ-
ent from vehicle, p < .001. †, Value significantly different from PHE alone, p < .01.
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Effect of catalytically active and inactive PKCζ mutants on PLD activity Figure 6
Effect of catalytically active and inactive PKCζ mutants on PLD activity. A, Representative Western blot showing 
the transfection of pCMV-FLAG-PKCζ constructs using an anti-FLAG antibody. Samples were immunoprecipitated with anti-
FLAG antibody and probed with the same antibody; 1: untransfected, 2: pCMV-FLAG wt PKCζ, 3: pCMV-FLAG T410A PKCζ, 
4 and 5: pCMV-FLAG T410E PKCζ. B, Cells were transiently transfected with wt PKCζ, kinase-deficient T410A PKCζ and 
constitutively active T410E PKCζ for 48 h and PLD activity was determined as described in Methods. Data are expressed as 
the change in PLD activity as a fraction of basal activity (non transfected cells). Values are the mean ± S.E. of three independent 
experiments performed in duplicate on different batches of cells. * Value significantly different from basal p < .01. C, PHE-
induced increase in PLD activity was adjusted for basal variations in the absence of PHE (shown in panel B) for each treatment 
(vehicle, wt, T410A, T410E). PLD activity was calculated as [PKCζ construct + PHE / [PKCζ construct alone]. This data pres-
entation allows the elimination of non specific variations of basal PLD activity due to the overexpression of the PKCζ con-
structs. Values are the mean ± S.E. of three independent experiments performed in duplicate on different batches of cells. * 
Value significantly different from vehicle, p < .01.
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PHE. Therefore, α1A AR expression and/or function are not
altered by transfection of PKCζ mutants. These results also
indicate the lack of deleterious effect or toxicity of PKCζ
overexpression on the α1A adrenergic signaling pathway.
A PKCζ inhibitor blocks PHE-induced PLD activity
The specific PKCζ inhibitor, PSζ [33], was used to selec-
tively inhibit PKCζ activity (Fig. 5B). Surprisingly, PHE-
induced PLD activation was blocked with 50 µM PSζ (Fig.
8), suggesting a specific role for the PKCζ pseudosubstrate
domain in the regulation of PLD activity. Myristoylated
PKC(20–28) peptide inhibitor (50 µM), a selective inhib-
itor of classical PKCs such as PKCα or PKCβ1/2, did not
alter PLD activity (4.24 ± 0.34 fold increase with 2 µM
PHE versus 4.09 ± 0.03 fold increase with PHE + PKC(20–
28) peptide inhibitor).
Effect of PKCζ mutants on p38 phosphorylation Figure 7
Effect of PKCζ mutants on p38 phosphorylation. A, Cells were transiently transfected with wt PKCζ, kinase-deficient 
T410A PKCζ and constitutively active T410E PKCζ for 48 h and treated with or without PHE for 5 min. Phospho-p38 and p38 
protein levels in cell lysates were determined by western blot analysis as described in Methods. The bar graph (B) represents 
quantification of the ratio phospho-p38 / 38 protein bands by densitometric analysis of blots from four different experiments. * 
denotes value significantly different from vehicle (nontransfected and lipofectamine-treated cells), p < .01.
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Discussion
This study confirms that stimulation of α1A AR with PHE
in rat-1 fibroblasts promotes activation of a PLD activity
[10,11,25]. Moreover, it demonstrates that PHE selec-
tively decreases PKCζ activity and that PLD activity is reg-
ulated by a mechanism involving PKCζ. Furthermore, the
pseudosubstrate domain of PKCζ appears to play an
important role in the regulation of PLD. Our previous
study has ruled out the involvement of classical or novel
PKC isoforms in α1A AR-stimulated PLD activation [25].
In rat-1 fibroblasts expressing the α1A AR subtype, PHE
causes a transient Ca2+ increase, cAMP accumulation and
activation of PKA, p38 mitogen-activated protein kinase,
p70 S6 kinase and PLD activation [10,11,23,34]. In con-
trast, PHE inhibits basal levels or agonist-induced activa-
tion of ERK, PI 3-kinase and Akt in these cells [11,34]. In
addition, PHE slightly decreases basal PtdInsP2  and
PtdInsP3 levels [34]. Despite these negative effects on pro-
liferation (ERK) and survival (PI 3-kinase, Akt) pathways
in rat-1 fibroblasts, α1A AR stimulation does not signifi-
cantly promote apoptosis [34]. It should be noted that in
these cells, PLD activity is extremely low both in serum-
deprived or serum-treated cells; PLD activation by PHE is
not affected by the presence of serum and PHE decreases
cell proliferation (Parmentier JH, Saeed AE and Malik KU,
our unpublished observation). These observations,
together with our finding that PHE-induced decrease in
PKCζ activity is associated with an increase in PLD
activity, support an anti-proliferative effect of α1A AR stim-
ulation in rat-1 fibroblasts, involving PLD activation. In
contrast, in VSMC expressing high levels of the PLD2
isoform [30,32], norepinephrine-induced cell prolifera-
tion was dependent on PLD activation. In addition,
Effect of the pseudosubstrate peptide inhibitor of PKCζ (PSζ) on PLD activity Figure 8
Effect of the pseudosubstrate peptide inhibitor of PKCζ (PSζ) on PLD activity. Cells were pretreated with 50 µM 
myristoylated PSζ for 1 hour before the addition of 2 µM PHE for 15 min. PLD activity was then measured as described in 
Methods. Data are expressed as the fold increase in PLD activity above basal (untreated cells). * Value significantly different 
from PHE alone, p < .05.
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norepinephrine selectively stimulates the PLD2 isoform
in VSMC [32] through the catalytic activation of PKCζ
[30], in contrast to the effect of PHE in rat-1 fibroblasts.
The cell phenotype, VSMC vs. rat-1 fibroblasts, or the
adrenergic receptor subtype, α1A AR in rat-1 vs. several α1
and α2 AR subtypes in VSMC, may be responsible for this
difference.
To our knowledge, this is the first report demonstrating
inhibition of PKCζ activity in response to receptor stimu-
lation. However, treatment with PHE decreases the activ-
ity of many mitogenic indices in rat-1 fibroblasts,
including DNA synthesis, ERK, phosphatidylinositol 3-
kinase and Akt [11,34]. A noteworthy fact is that there is
elevated mitogenic signaling in rat-1 fibroblasts express-
ing α1A AR cultured in serum-free medium. The decrease
in PKCζ activity elicited by PHE could result from a phys-
ical interaction between PKCζ and K10 keratin, causing
sequestration of PKCζ within the cytoskeleton and pre-
venting its intracellular translocation, thus impairing its
activation, as reported by Paramio et al. [35], although
translocation is often associated with activation for other
PKC isoforms. In addition, a recent study shows that a
small pool of PKCζ is constitutively active and bound to
14-3-3 zeta in the brain [22], a mechanism that could
account for the persistent activation of PKCζ in rat-1
fibroblasts. PI 3-kinase, an upstream activator required for
PKCζ activation, is also inhibited by PHE in rat-1
fibroblasts [34]. Recently, it has been demonstrated that
atypical PKC activation is dependent on PLD activity [27-
29]. However, our data show that PLD activation with
PHE was associated with a decrease in PKCζ activity in rat-
1 fibroblasts.
Our data also shows that the decrease in PKCζ activity
elicited by PHE is not matched by a decrease in the
phosphorylation of Thr 410. PKCζ is maintained in an
inactive state by direct binding of the N-terminal
pseudosubstrate domain to the C-terminal catalytic
domain [13]. Phosphorylation of the activation loop at
Thr 410 is necessary and sufficient to activate the kinase
function of PKCζ after autophosphorylation of Thr 560
[36-38]. In VSMC, we observed a simultaneous increase in
PKCζ phosphorylation and activity in response to nore-
pinephrine [30]. However, at 5 min of stimulation, PKCζ
phosphorylation continued to increase whereas PKCζ
activity was already decreasing [30]. Therefore, although
phosphorylation at Thr 410 is a prerequisite for PKCζ acti-
vation as shown by different studies [36-38], it is not clear
if dephosphorylation of Thr 410 is a prerequisite for its
inactivation. It has been recently reported that in fact
phosphorylation of Thr 410 and subsequent autophos-
phorylation of Thr 560 targets PKCζ towards proteosomal
degradation [39]. Moreover, proteins that bind to PKCζ
may directly inhibit its activity. For example, PAR-4, prod-
uct of a gene induced during apoptosis, inhibits atypical
PKCζ and PKCλ/ι activity through direct protein-protein
interaction [40]. This mechanism of inhibition of PKCζ
activity may not require dephosphorylation of the
enzyme. Thus, phosphorylation at Thr 410 seems to be
required for PKCζ activation whereas inhibition of PKCζ
activity seems to be independent of Thr 410 dephosphor-
ylation and may involve other proteins. Since PKCζ
immunoprecipitation and assay were carried out in non-
denaturing conditions, it is likely that the interaction of
PKCζ with other proteins, such as with an endogenous
inhibitor, is conserved during the assay.
The activation of PLD elicited by PHE may be independ-
ent of PKCζ catalytic activity since constitutively active
T410E PKCζ did not alter the extent of PHE-induced PLD
activation. It is widely accepted that PKCζ activates down-
stream targets through a phosphorylation-dependent
mechanism. However, it has been reported that atypical
PKCζ may also directly stimulate MEK5/ERK5 pathway
through its N-terminal regulatory domain (containing the
pseudosubstrate site), independent of its catalytic activity
[41]. Therefore, PKCζ may stimulate downstream targets
independent of its activity and phosphorylation state.
Moreover, the actual proposed mechanism of PLD1 acti-
vation by the classical isoform PKCα is independent of the
catalytic activity of PKC [26]. In contrast, the fact that cat-
alytically inactive PKCζ potentiated PLD activity and
PKCζ activity was decreased after PHE stimulation indi-
cate that an initial decrease in PKCζ activity may be
required for a non-catalytic PKCζ-dependent activation of
PLD activity. On the other hand, the decrease in PKCζ
activity could be a consequence and not a prerequisite for
this potential mechanism of action.
Regulation of PLD activity by PKCζ may involve the pseu-
dosubstrate domain or a regulatory domain of PKCζ. PSζ
is utilized to inhibit PKCζ activity [14,30]. However, we
show that PHE is a better inhibitor than PSζ and PSζ fur-
ther blocks the decrease in PKCζ activity elicited by PHE.
These data and the lack of decrease in PKCζ phosphoryla-
tion suggest that other proteins activated by PHE may be
involved in reducing PKCζ activity. In addition, PSζ
blocked PHE-induced PLD activation. Therefore, PSζ may
alter PKCζ function(s) through two different actions.
First, it inhibits kinase activity through binding to the cat-
alytic site, which mimics the endogenous pseudosubstrate
domain [14,33]. Second, it may act a competitive inhibi-
tor of the interaction of the regulatory N-terminal
domains (PB1, PS, C1) [42,43] of PKCζ with other
effectors, such as PAR, MEK5, p62/ZIP, tubulin or other
proteins [20,21,40,41,44,45]. PKCζ directly stimulates
the MEK5/ERK5 pathway through its N-terminal
regulatory domain independently of its catalytic activity
[41]. PSζ may competitively inhibit the interaction of theBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/4
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regulatory domain with a protein containing an aPKC
interaction domain, such as MEK-5 or the scaffold protein
p62, in addition to its effect on catalytic activity. This
mechanism of action would explain the effect of PSζ on
PLD activity and PKCζ activity. It should be noted that a
PKCα pseudosubstrate inhibitor did not alter PHE-
induced PLD activity (Fig. 8), underscoring the selectivity
of myristoylated PSζ.
An alternative hypothesis involves a PKCζ-mediated PLD
phosphorylation that would keep PLD inactive when
PKCζ is active. However, our data do not support this,
since kinase inactive PKCζ or myristoylated PSζ did not
stimulate PLD activity in the absence of PHE stimulation.
Moreover, PLD phosphorylation is probably not involved
in its mechanism of activation [3].
PKCα, the only classical isoform found in rat-1 fibroblasts
expressing α1A AR, was not activated, as previously shown
in these cells [24]. A previous study by Taguchi et al. [11]
showed an increase in PKCα translocation in response to
PHE in the same cell model. The main difference between
the two studies resides in the PHE concentration, 2 µM
PHE in our work vs. 100 µM PHE [11], indicating that
PHE is able to significantly stimulate PKCα translocation
at concentration higher than 2 µM.
Conclusions
Our data indicate that a non-constitutively active PLD iso-
form expressed in rat-1 fibroblasts is regulated by a PKCζ-
dependent mechanism following α1A AR stimulation by
PHE. The exact mechanism of PLD activation by PKCζ is
still unknown and may be independent of the catalytic
activity. Our data show the possible regulation of PLD by
a mechanism involving the pseudosubstrate or the
regulatory domain of PKCζ. Further characterization of
the mechanism of PLD activation and the possible inter-
action of PLD isoforms with PKCζ should provide impor-
tant information about its regulation and its functional
significance in rat-1 fibroblasts.
Methods
Materials
Phenylephrine was obtained from Sigma (St. Louis, MO);
phorbol-12-myristate-13-acetate (PMA) from Calbio-
chem (San Diego, CA); myristoylated PKCζ and PKCα/β
(20–28) peptide inhibitors from Biomol (Plymouth
Meeting, PA); [3H]oleic acid (50 Ci/mmol) from Ameri-
can Radiolabeled Chemicals (St. Louis, MO); [γ-32P]ATP
(3000 Ci/mmol) from Amersham (Arlington Heights, IL).
Antibodies to PKCα, PKCζ and p38 were from Santa-Cruz
Biotechnology (Santa Cruz, CA); phospho-PKCζ/λ and
phospho-p38 antibodies were from Cell Signaling Tech-
nology (Beverly, MA).
Cell culture
Rat-1 fibroblasts were stably transfected with bovine α1A
AR (a kind gift from Drs. L.F. Allen and R.J. Lefkowitz
(Howard Hughes Medical Institute, Duke University Med-
ical Center, Durham, NC). Cells were maintained under
5% CO2 at 37°C in Dulbecco's modified Eagle's medium
(DMEM) containing 50 units of penicillin, 50 µg of strep-
tomycin per ml, and 10% fetal bovine serum (FBS). Selec-
tion and maintenance of stably transfected cells were
carried out with 400 µg/ml G418 (Invitrogen, San Diego,
CA).
Transient transfection
Rat-1 fibroblasts were transiently transfected with pCMV-
FLAG-wt-PKCζ, pCMV-FLAG-T410A-PKCζ (kinase inac-
tive), pCMV-FLAG-T410E-PKCζ (constitutively active)
vectors (gift from Dr. A. Toker, BBRI, Boston, MA and R.
Farese, USF, Tampa, FL) using Lipofectamine PLUS (Invit-
rogen). Efficiency of transfection was determined by West-
ern blot analysis using an anti-FLAG antibody (Sigma).
Transfection of rat-1 fibroblasts was performed for 2 days
before assays with cells washed 8 hours after transfection
to avoid lipofectamine-induced cytotoxicity.
Phospholipase D assay
PLD activity was quantitated by the formation of phos-
phatidylethanol according to a method previously
described for rat-1 fibroblast [10]. Briefly, serum-starved
rat-1 fibroblasts in 6-well plates were labeled overnight
with [3H]oleic acid (1 µCi/ml) in DMEM. Cells were then
incubated with inhibitors and exposed to PHE (2 µM) for
15 minutes in the presence of 200 mM ethanol. Rat-1
fibroblasts were scraped into 2 ml ice-cold methanol and
HCl solution, and 1 ml chloroform was added. Lipids
were separated by chloroform extraction. A 40 µl aliquot
was removed from the chloroform phase to determine the
content of radioactivity in the total lipid fraction. The
chloroform phase (0.8 ml) was evaporated under nitro-
gen and redissolved in 50 µl chloroform/methanol (9:1)
containing phosphatidylethanol standard. Samples were
spotted onto a silica gel thin-layer chromatography plate,
and lipids were separated with the solvent system of chlo-
roform/acetone/methanol/HCl/water
(50:20:12.5:10:7.5). Phosphatidylethanol was identified
by the mobility of authentic standard visualized with
iodine vapor. Lanes containing phosphatidylethanol were
scraped, and radioactivity was measured by scintillation
spectroscopy. Data were measured as the ratio of
[3H]phosphatidylethanol to [3H]total lipids.
PKCζ assay
The activity of PKCζ was determined according to the
method described [14,24]. Rat-1 fibroblasts in 100 mm
dish were washed with PBS and scraped in 1 ml RIPA
buffer [50 mM Tris.Cl, pH 7.4; 150 mM NaCl, 1%BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/4
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IGEPAL, 1 mM EDTA] containing protease and phos-
phatase inhibitors [1 µg/ml aprotinin, 1 µg/ml leupeptin,
1 mM PMSF, 1 mM Na orthovanadate, 1 mg/ml p-nitro-
phenyl-phosphate]. Total cell lysates were incubated with
rabbit polyclonal PKCζ antibody (Santa Cruz Biotechnol-
ogy, CA) for three hours and the immunocomplex was
captured with a 50% slurry of protein A agarose beads.
PKCζ immunoprecipitates were washed twice with high
salt [50 mM Tris.Cl, pH 7.5; 10 mM MgCl2; 0.5 M LiCl]
and low salt [50 mM Tris.Cl, pH 7.5; 10 mM MgCl2] buff-
ers, and incubated with a kinase buffer [50 mM Tris.Cl,
pH 7.5; 10 mM MgCl2; 0.2 mM EGTA, 50 µM ATP] con-
taining 50 µM ε-peptide and 3 µCi [γ-32P]ATP at 30°C.
The reaction was stopped by the addition of 200 mM
EDTA and the proteins were precipitated by the addition
of 25% TCA. The solutions were centrifuged for one
minute at 14,000 rpm, and supernatants spotted onto p81
phosphocellulose filters. Filters were washed with 1% (v/
v) orthophosphoric acid and analyzed by Cerenkov
counting. PKCζ activity was calculated from the amount
of 32P incorporated into the ε-peptide.
Western blot Analysis
Total cell lysate was prepared in modified RIPA buffer
containing protease and phosphatase inhibitors and pro-
tein concentration was determined by the Bradford
method. Proteins in 50 µg of lysate were separated by
SDS-PAGE and blotted onto nitrocellulose membranes.
Blots were incubated with antibodies at dilutions recom-
mended by the manufacturers (Cell Signaling Technology
and Santa-Cruz Biotechnology). The blots were visualized
with the ECL plus detection system (Amersham Pharma-
cia, Piscataway, NJ). For PKCζ phosphorylation at Thr
410, an indicator of PKCζ kinase activity, a phospho-
PKCζ/λ antibody was used. Blots were also stripped off
with a stripping buffer [100 mM β-mercaptoethanol; 62.5
mM Tris.Cl, pH 6.7, 2% SDS] for 30 min at 50°C, washed
twice with TBST, and reprobed with nPKCζ or p38
antibody.
Cell Fractionation
For experiments involving cell fractionation, cells cultured
in 150 mm dishes (two per treatment) were scraped in
fractionation buffer (10 mM Tris-HCl [pH 7.5], 10 mM
NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM PMSF, 10 µg/
ml leupeptin, 10 µg/ml aprotinin, 1 mM sodium
orthovanadate, 10 µg/ml trypsin inhibitor), subjected to
25 passes in a Potter-type teflon-on-glass homogenizer
with a loose fitting and centrifuged at 700 × g for 5 min.
The supernatant was centrifuged at 100,000 × g for 30
min, and the cytosolic fraction was stored at -80°C. The
particulate fraction was resuspended in 1% Triton-RIPA
buffer, sonicated, and stored at -80°C. 50 µg aliquots of
each fraction were analyzed by Western-blot.
Data analysis
The results are expressed as mean ± SE. The data were ana-
lyzed by one-way ANOVA. The unpaired Student's t-test
was applied to determine the difference between two
groups, and the Newman-Keuls' a posteriori test to deter-
mine the difference between multiple groups. A value of P
= 0.05 was considered significant. PLD activity was
expressed as either 1000 × [3H]phosphatidylethanol /
[3H]total lipids, or as a fraction of the basal or as the fold
increase over vehicle. The phosphoprotein and protein
level were estimated by densitometric analysis of the
Western blots and performed on the indicated number of
blots using NIH Image software, and expressed as a fold
increase or decrease (mean ± SE) of the control, arbitrarily
chosen as 1.
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